Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Gastric Cancer

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 35 articles: HTML format

Single Articles

October 2024
1. PAVLAKIS N, Shitara K, Sjoquist K, Martin A, et al
   INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer.
   J Clin Oncol. 2024 Oct 4:JCO2400055. doi: 10.1200/JCO.24.00055.
   PubMed     Abstract available
   
   
   July 2024
2. KANG YK, Kim HD, Yook JH, Park YK, et al
   Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.
   J Clin Oncol. 2024 Jul 12:JCO2302167. doi: 10.1200/JCO.23.02167.
   PubMed     Abstract available
   
   
   June 2024
3. SORSCHER S
   Helicobacter pylori and Gastric Cancer Screening.
   J Clin Oncol. 2024 Jun 27:JCO2400509. doi: 10.1200/JCO.24.00509.
   PubMed    
   
   
   
4. HEGEWISCH-BECKER S, Mendez G, Chao J, Nemecek R, et al
   First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.
   J Clin Oncol. 2024;42:2080-2093.
   PubMed     Abstract available
   
   
   
5. JANJIGIAN YY, Ajani JA, Moehler M, Shen L, et al
   First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.
   J Clin Oncol. 2024;42:2012-2020.
   PubMed     Abstract available
   
   
   
6. BUTT J, Epplein M
   Potent Tool: Helicobacter pylori Treatment to Reduce the Risk of Both Gastric and Colorectal Cancers.
   J Clin Oncol. 2024;42:1865-1867.
   PubMed    
   
   
   March 2024
7. SALANI F, Vivaldi C, Rreka E, Genovesi V, et al
   Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Carcinomatosis: The Need for Clear Answers Through Proper Questions.
   J Clin Oncol. 2024 Mar 14:JCO2302611. doi: 10.1200/JCO.23.02611.
   PubMed    
   
   
   February 2024
8. ZHU M, Yoon HH
   Neoadjuvant Immunotherapy in Gastroesophageal Cancer: A Promising Early Signal?
   J Clin Oncol. 2024;42:373-377.
   PubMed    
   
   
   
9. GALLANIS AF, Gamble LA, Samaranayake SG, Lopez R, et al
   Costs of Cancer Prevention: Physical and Psychosocial Sequelae of Risk-Reducing Total Gastrectomy.
   J Clin Oncol. 2024;42:421-430.
   PubMed     Abstract available
   
   
   December 2023
10. MOEHLER M, Xiao H, Blum SI, Elimova E, et al
    Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.
    J Clin Oncol. 2023;41:5388-5399.
    PubMed     Abstract available
    
    
    November 2023
11. LORENZEN S, Gotze TO, Thuss-Patience P, Biebl M, et al
    Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.
    J Clin Oncol. 2023 Nov 14:JCO2300975. doi: 10.1200/JCO.23.00975.
    PubMed     Abstract available
    
    
    
12. DEL RIVERO J, Perez K, Kennedy EB, Mittra ES, et al
    Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
    J Clin Oncol. 2023;41:5049-5067.
    PubMed     Abstract available
    
    
    October 2023
13. RAU B, Lang H, Koenigsrainer A, Gockel I, et al
    Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial.
    J Clin Oncol. 2023 Oct 31:JCO2202867. doi: 10.1200/JCO.22.02867.
    PubMed     Abstract available
    
    
    
14. LEE CK, Kim HS, Jung M, Kim H, et al
    Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study.
    J Clin Oncol. 2023 Oct 26:JCO2300971. doi: 10.1200/JCO.23.00971.
    PubMed     Abstract available
    
    
    September 2023
15. KIM CG, Jung M, Kim HS, Lee CK, et al
    Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer.
    J Clin Oncol. 2023;41:4394-4405.
    PubMed     Abstract available
    
    
    March 2023
16. SHAH MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, et al
    Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
    J Clin Oncol. 2023;41:1470-1491.
    PubMed     Abstract available
    
    
    February 2023
17. YAMAGUCHI K, Bang YJ, Iwasa S, Sugimoto N, et al
    Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.
    J Clin Oncol. 2023;41:816-825.
    PubMed     Abstract available
    
    
    January 2023
18. ANDRE T, Tougeron D, Piessen G, de la Fouchardiere C, et al
    Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
    J Clin Oncol. 2023;41:255-265.
    PubMed     Abstract available
    
    
    November 2022
19. HOFHEINZ RD, Merx K, Haag GM, Springfeld C, et al
    FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.
    J Clin Oncol. 2022;40:3750-3761.
    PubMed     Abstract available
    
    
    August 2022
20. MARON SB, Moya S, Morano F, Emmett MJ, et al
    Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.
    J Clin Oncol. 2022;40:2458-2467.
    PubMed     Abstract available
    
    
    July 2022
21. PATEL MA, Kratz JD, Lubner SJ, Loconte NK, et al
    Esophagogastric Cancers: Integrating Immunotherapy Therapy Into Current Practice.
    J Clin Oncol. 2022 Jul 15:JCO2102500. doi: 10.1200/JCO.21.02500.
    PubMed     Abstract available
    
    
    June 2022
22. GWEE YX, Chia DKA, So J, Ceelen W, et al
    Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis.
    J Clin Oncol. 2022 Jun 1:JCO2102745. doi: 10.1200/JCO.21.02745.
    PubMed     Abstract available
    
    
    March 2022
23. KIM YW, Min JS, Yoon HM, An JY, et al
    Laparoscopic Sentinel Node Navigation Surgery for Stomach Preservation in Patients With Early Gastric Cancer: A Randomized Clinical Trial.
    J Clin Oncol. 2022 Mar 24:JCO2102242. doi: 10.1200/JCO.21.02242.
    PubMed     Abstract available
    
    
    February 2022
24. ZHAO JJ, Yap DWT, Chan YH, Tan BKJ, et al
    Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
    J Clin Oncol. 2022;40:392-402.
    PubMed     Abstract available
    
    
    September 2021
25. MO DC, Qin L, Ye LJ
    Neoadjuvant Docetaxel, Oxaliplatin, and S-1 in Resectable Advanced Gastric Cancer.
    J Clin Oncol. 2021 Sep 30:JCO2101528. doi: 10.1200/JCO.21.01528.
    PubMed    
    
    
    
26. KANG YK, Yook JH, Park YK, Lee JS, et al
    PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.
    J Clin Oncol. 2021;39:2903-2913.
    PubMed     Abstract available
    
    
    August 2021
27. TEH SH, Uong S, Lin TY, Shiraga S, et al
    Clinical Outcomes Following Regionalization of Gastric Cancer Care in a US Integrated Health Care System.
    J Clin Oncol. 2021 Aug 2:JCO2100480. doi: 10.1200/JCO.21.00480.
    PubMed     Abstract available
    
    
    March 2021
28. HAFFNER I, Schierle K, Raimundez E, Geier B, et al
    HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study.
    J Clin Oncol. 2021 Mar 25:JCO2002761. doi: 10.1200/JCO.20.02761.
    PubMed     Abstract available
    
    
    
29. VAN DER VEEN A, Brenkman HJF, Seesing MFJ, Haverkamp L, et al
    Laparoscopic Versus Open Gastrectomy for Gastric Cancer (LOGICA): A Multicenter Randomized Clinical Trial.
    J Clin Oncol. 2021;39:978-989.
    PubMed     Abstract available
    
    
    
30. SHAH MA, Bodoky G, Starodub A, Cunningham D, et al
    Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1).
    J Clin Oncol. 2021;39:990-1000.
    PubMed     Abstract available
    
    
    January 2021
31. LU Z, Fang Y, Liu C, Zhang X, et al
    Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial.
    J Clin Oncol. 2021 Jan 8:JCO2001254. doi: 10.1200/JCO.20.01254.
    PubMed     Abstract available
    
    
    November 2020
32. MOEHLER M, Dvorkin M, Boku N, Ozguroglu M, et al
    Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100.
    J Clin Oncol. 2020 Nov 16:JCO2000892. doi: 10.1200/JCO.20.00892.
    PubMed     Abstract available
    
    
    July 2020
33. CATENACCI DVT, Rasco D, Lee J, Rha SY, et al
    Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma.
    J Clin Oncol. 2020;38:2418-2426.
    PubMed     Abstract available
    
    
    June 2020
34. MAKIYAMA A, Sukawa Y, Kashiwada T, Kawada J, et al
    Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).
    J Clin Oncol. 2020;38:1919-1927.
    PubMed     Abstract available
    
    
    April 2020
35. FUKUOKA S, Hara H, Takahashi N, Kojima T, et al
    Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).
    J Clin Oncol. 2020 Apr 28:JCO1903296. doi: 10.1200/JCO.19.03296.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gastric Cancer is free of charge.